Kymera Therapeutics, Inc. KYMR Stock Forecast
AI-powered price prediction and analysis for Kymera Therapeutics, Inc. · Alpha · vs marketSwitch to Total
See KYMR's Exact Price Target · Create a free account and follow this stock to unlock its full AI forecast — 3 stocks free.
Price Chart
Key Statistics
About Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc. (KYMR) operates within the Life Sciences sector, specifically in the Biological Products, (No Diagnostic Substances) industry.
Latest News
Where KYMR sits on the market map
Biological Products, (No Diagnostic Substances) Peers
Companies sharing the same SEC industry code, one row per issuer, largest first - a classification match, not a curated list of competitors.
| Company | AI Signal | Market Cap | P/E |
|---|---|---|---|
| KYMR Kymera Therapeutics, Inc. | $10.60B | – | |
| AMGN Amgen Inc | $251.64B | 28.9x | |
| GILD Gilead Sciences, Inc. | $211.20B | – | |
| MRNA Moderna, Inc. | $88.16B | – | |
| ARGX Argenx Se | $54.15B | 23.0x | |
| RVMD Revolution Medicines, Inc. | $40.33B | – | |
| BIIB Biogen Inc. | $36.53B | 107.3x | |
| BNTX Biontech Se | $22.30B | 2.3x | |
| EXEL Exelixis, Inc. | $17.38B | 25.2x | |
| NBIX Neurocrine Biosciences Inc | $14.88B | 21.2x | |
| HALO Halozyme Therapeutics, Inc. | $14.86B | 30.1x | |
| TECH Bio-Techne Corp | $11.40B | 62.7x | |
| RGEN Repligen Corp | $11.06B | – | |
| QGEN Qiagen N.V. | $10.92B | 35.7x | |
| PCVX Vaxcyte, Inc. | $9.02B | – | |
| KRYS Krystal Biotech, Inc. | $8.76B | 40.2x | |
| IBRX Immunitybio, Inc. | $8.43B | – | |
| TWST Twist Bioscience Corp | $8.09B | – | |
| KOD Kodiak Sciences Inc. | $6.23B | – | |
| IMVT Immunovant, Inc. | $5.87B | – | |
| CGON Cg Oncology, Inc. | $5.49B | – | |
| SRRK Scholar Rock Holding Corp | $5.23B | – | |
| CRSP Crispr Therapeutics Ag | $4.83B | – | |
| ADPT Adaptive Biotechnologies Corp | $4.50B | – | |
| RLAY Relay Therapeutics, Inc. | $4.02B | – | |
| IOVA Iovance Biotherapeutics, Inc. | $3.63B | – | |
| TARS Tarsus Pharmaceuticals, Inc. | $3.26B | – | |
| DNLI Denali Therapeutics Inc. | $3.03B | – | |
| LIFE Atyr Pharma Inc | $2.72B | – | |
| BEAM Beam Therapeutics Inc. | $2.67B | 369.6x | |
| ADMA Adma Biologics, Inc. | $2.48B | 17.8x | |
| RXRX Recursion Pharmaceuticals, Inc. | $2.29B | – | |
| VCEL Vericel Corp | $2.20B | 116.0x | |
| BCRX Biocryst Pharmaceuticals Inc | $2.16B | – | |
| VIR Vir Biotechnology, Inc. | $1.99B | – | |
| COAG Hemab Therapeutics Holdings, Inc. | $1.92B | – | |
| MESO Mesoblast Ltd | $1.86B | – | |
| MAZE Maze Therapeutics, Inc. | $1.69B | – | |
| NVAX Novavax Inc | $1.66B | – | |
| ALVO Alvotech | $1.66B | – | |
| REPL Replimune Group, Inc. | $1.66B | – | |
| IMCR Immunocore Holdings Plc | $1.53B | – | |
| TSHA Taysha Gene Therapies, Inc. | $1.30B | – | |
| VOR Vor Biopharma Inc. | $1.14B | – | |
| IMTX Immatics N.V. | $965M | – | |
| CGEM Cullinan Therapeutics, Inc. | $961M | – | |
| ODTX Odyssey Therapeutics, Inc. | $939M | – | |
| MGTX Meiragtx Holdings Plc | $932M | 12.6x | |
| GLUE Monte Rosa Therapeutics, Inc. | $907M | – | |
| PRME Prime Medicine, Inc. | $805M | – | |
| SLBT Sl Science Holding Ltd | $724M | – | |
| SANA Sana Biotechnology, Inc. | $718M | – | |
| SLDB Solid Biosciences Inc. | $665M | – | |
| DNA Ginkgo Bioworks Holdings, Inc. | $663M | – | |
| FDMT 4d Molecular Therapeutics, Inc. | $628M | – | |
| AURA Aura Biosciences, Inc. | $625M | – | |
| CADL Candel Therapeutics, Inc. | $621M | – | |
| DBVT Dbv Technologies S.A. | $536M | – | |
| ENTX Entera Bio Ltd. | $535M | 9.4x | |
| VALN Valneva Se | $525M | – |
FAQ
Is Kymera Therapeutics, Inc. a good stock to buy?
Our AI analyzes Kymera Therapeutics, Inc. daily. Check the signal above for the latest recommendation. Always do your own research before investing.
How accurate are Kymera Therapeutics, Inc. predictions?
For KYMR, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -14.0%, measured on 358 forecast dates between 2022-08-16 and 2026-08-05 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 6.0%, measured on 400 forecast dates between 2022-08-16 and 2026-10-02. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are forecasts updated?
Kymera Therapeutics, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 3, 2026.
Ready to invest smarter? · Join thousands of investors using AI-powered stock predictions
Sign Up FreeLooking for a deeper analysis of Kymera Therapeutics, Inc.? View full institutional-grade analysis on Intratio →
AI predictions are based on historical patterns and should not be the sole basis for investment decisions. Past performance does not guarantee future results. Always do your own research.